Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular AMD

NCT05637255 is registered in ClinicalTrials.gov with Sylentis, S.A. as lead sponsor.

NCT NCT05637255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05637255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular AMD
Lead sponsor
Sylentis, S.A.
Phase
Phase 2
Overall status
Completed
Start date
November 22, 2022
Completion date
December 19, 2024
Enrollment
99 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration, neovascular age-related macular degeneration, wet macular degeneration